Compare FVCB & NYXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FVCB | NYXH |
|---|---|---|
| Founded | 2007 | 2009 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | Major Banks | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 229.7M | 188.1M |
| IPO Year | N/A | 2021 |
| Metric | FVCB | NYXH |
|---|---|---|
| Price | $16.05 | $4.61 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $16.00 | $11.67 |
| AVG Volume (30 Days) | 40.4K | ★ 44.5K |
| Earning Date | 01-20-2026 | 03-12-2026 |
| Dividend Yield | ★ 1.50% | N/A |
| EPS Growth | ★ 47.56 | N/A |
| EPS | ★ 1.21 | N/A |
| Revenue | ★ $65,816,999.00 | $6,616,215.00 |
| Revenue This Year | $9.22 | $75.27 |
| Revenue Next Year | $7.13 | $277.15 |
| P/E Ratio | $13.21 | ★ N/A |
| Revenue Growth | ★ 13.25 | 10.96 |
| 52 Week Low | $9.49 | $4.35 |
| 52 Week High | $16.34 | $11.87 |
| Indicator | FVCB | NYXH |
|---|---|---|
| Relative Strength Index (RSI) | 78.21 | 44.96 |
| Support Level | $15.61 | $4.70 |
| Resistance Level | $15.97 | $4.70 |
| Average True Range (ATR) | 0.42 | 0.17 |
| MACD | 0.08 | -0.03 |
| Stochastic Oscillator | 100.00 | 23.81 |
FVCBankcorp Inc is a registered bank holding company. It operates through the sole subsidiary, FVCbank which is a community-oriented, locally-owned, and managed commercial bank. It offers commercial banking services to small and medium-sized businesses, professionals, non-profit organizations and associations, and investors. It also provides retail banking services to accommodate the individual needs of both corporate customers as well as the communities it serves. The bank provides other facilities such as online banking, mobile banking, remote deposit service, and lending products, among others. Its primary source of revenue is the net interest income.
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.